CClinicalTrials.gg
WithdrawnNCT03242005Updated Sep 14, 2017

The PSIQS Study - User Experience With Pro-Set

An interventional study of MiniMed® Pro-set® and MiniMed® Quick-set® in Diabetes Mellitus, Type 1, sponsored by Becton, Dickinson and Company. Withdrawn. Open to participants aged 13 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by Becton, Dickinson and Company · Not applicable, Interventional, and Other

Why this study was withdrawn
Sponsor decision to not proceed with study - no subjects enrolled
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
13 Years to 70 Years
Sex
All
01

Study summary

Open label, randomized 2-period cross-over study comparing two continuous subcutaneous insulin infusion sets ; MiniMed® Pro-set® with BD FlowSmart™ technology and MiniMed® Quick-set®

02

Conditions studied

  • Diabetes Mellitus, Type 1
03

In context

Diabetes Mellitus, Type 1

3,522 studies on the registry are indexed under Diabetes Mellitus, Type 1; 577 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Becton, Dickinson and Company is the lead sponsor of 60 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Must be between 13 and 70 years of age (inclusive)
  • Must have been previously diagnosed with type 1 diabetes mellitus
  • Must be using one of the following Medtronic insulin pumps with the Paradigm connector (note 670G excluded) for at least 6 months prior to enrollment. These pumps must have the ability to upload data to Medtronic CareLink Therapy Management software.

    1. MiniMed Paradigm Revel™ Insulin Pump - models 523 (1.8 mL reservoir) and 723 (3 mL reservoir)
    2. MiniMed 530G Pump - models 551 (1.8 mL reservoir) and 751 (3 mL reservoir)
    3. MiniMed 630G System
  • Must have been using the Medtronic Enlite CGM for at least 3 months prior to enrollment, and are currently doing so
  • Must routinely insert their own infusion set (may be inserted manually or with an inserter or with an integrated set/inserter, i.e. Mio)
  • If instructed, must be willing to insert all assigned infusion sets with a mechanical inserter
  • Must have another form of insulin delivery available (i.e. vial and syringe or pen and pen needle)
  • Must agree to continue using current Medtronic Enlite CGM throughout the study
  • Willing to have insulin pump, BGM and CGM data downloaded into Medtronic CareLink Therapy Management Software (requires subject CareLink logon ID and password)
  • In stable health status with no acute or significant illness, in the opinion of the investigator or designee
  • Able to read, write and follow instructions in English
  • Able and willing to provide informed consent
  • Able and willing to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Pregnant (self-attestation) or nursing
  • Currently using a body-worn patch insulin infusion pump, e.g. Omnipod or V-Go
  • Currently using the Medtronic Model 670G pump and associated CGM
  • Current or past participation in previous BD Study DBC-16SCARL21
  • History of bleeding disorder or easy bruising.
  • Currently taking anti-platelet therapy or anticoagulants (use of up to 81 mg per day of aspirin is permitted).
  • Known blood borne infections.
  • History of recurrent dermatological condition or skin disorder (e.g. psoriasis, eczema, pre-existing dermatitis).
  • Skin abnormalities, anomalies or conditions (e.g. sunburn, tattoos, extensive scarring, lipohypertrophy) located at or very close to the intended insertion site.
  • Physical condition that restricts dexterity and may limit ability to perform study procedures (i.e. severe neuropathy or arthritis of the hands; self-reported)
  • Currently participating in any other clinical investigation that conflicts with this study
  • Employed by, or currently serving as a contractor or consultant to BD, Medtronic or study site
  • Any other condition the investigator or designee deems to pose an unacceptable risk to the subject in the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pro-set® vs. Quick-set®

    Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.

    Device: MiniMed® Pro-set® · Device: MiniMed® Quick-set®

Interventions

  • DeviceMiniMed® Pro-set®

    Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.

  • DeviceMiniMed® Quick-set®

    Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.

06

What researchers measure

Primary outcomes

  1. Compare Pro-set® vs. Quick-set® for non-inferiority for set insertion failures (set removal) due to either occlusion alerts or hyperglycemia

    Time frame: 6 hours from time of insertion

Secondary outcomes

  1. Compare Pro-set® vs. Quick-set® for set removals due to hyperglycemia; > 400mg/dl.

    Time frame: 6 hours from time of insertion

  2. Compare Pro-set® vs. Quick- set® for set removals due to set failure; hyperglycemia >250mg/dl.

    Time frame: 72 hours of set wear that occurs at 6 hours or later after insertion

  3. Compare Pro-set® vs. Quick- set® for set removals at less than 60 hours post insertion.

    Time frame: 60 hours post insertion

  4. Compare Pro-set® vs. Quick- set® for duration of wear

    Time frame: % reaching 12 hours, % reaching 24 hours, % reaching 36 hours, % reaching 48 hours, % reaching 60 hours, and % reaching 72 hours)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03242005
Lead sponsor
Becton, Dickinson and Company
Responsible party
Sponsor
First posted
Aug 8, 2017
Start date
Sep 2017 (estimated)
Primary completion
Dec 2017 (estimated)
Completion
Feb 2018 (estimated)
Last update
Sep 14, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion